Overview

A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
No investigational drug will be administered in this study for the treatment of Fabry disease. This will be a multicenter, multinational, non-treatment, cross-sectional study of young male patients with Fabry disease who have not yet initiated interventional treatment for this disease. The study will consist of a screening visit(s), a clinical investigation visit(s), and a follow-up phone contact. The objectives of the study are: - To document renal function and other Fabry disease manifestations across age in treatment-naïve, young male patients with Fabry disease. - To provide a reference group for comparison with interventional clinical trials of Fabry disease. The duration of each patient's participation in the study, inclusive of the screening visit and follow-up phone contact, will be approximately 12 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Genzyme, a Sanofi Company